Go to top of page

CEO decision - ANSTO Nuclear Medicine Molybdenum-99 facility

4 October 2014

CEO decision - ANSTO Nuclear Medicine Molybdenum-99 facility

On 4 October 2013, the CEO of ARPANSA decided issue a licence to the Australian Nuclear Science and Technology Organisation (ANSTO) to prepare a site for a controlled facility (the ANSTO Nuclear Medicine Molybdenum-99 Facility) at the ANSTO Lucas Heights Science and Technology Centre.

Download a copy of the CEO’s Statement of Reasons:

PDF iconCEO decision - ANSTO Nuclear Medicine Mlybdenum-99 facility - Statement of Reasons
Microsoft Office document iconCEO decision - ANSTO Nuclear Medicine Mlybdenum-99 facility - Statement of Reasons

In making his decision the CEO of ARPANSA took into consideration the documentation submitted by ANSTO in support of the application as well as:

The licence is subject to the standard condition relating to compliance reporting, training and work practices but I have not imposed any special licence conditions relating specifically to the proposed facility.

The licence remains in force until it is cancelled or suspended under section 38 of the Act or until it is surrendered under section 39 of the Act.

The associated application to site and construct the ANSTO Sy-Mo prescribed radiation facility is currently under regulatory review.

Looking for more information?

If you'd like to know more about the applications or the process for review see the ANSTO Mo99 and SyMo application information and ANM Mo99 and ANSTO Sy-Mo Facility Licence Applications pages.

If you'd like to know more about the public consultation process that’s been undertaken or view the submissions and transcript from the public information session, see the Regulatory Services Public Consultation page.

Contact information

For media queries please contact: mediaatarpansa.gov.au